5 new projects to be supported by the PSCC

5 new promising start-ups have been selected by the PSCC to join its bustling community and benefit from a world-class ecosystem, bringing the total number of cutting-edge initiatives supported by the oncocluster to 66

🔹GMT Science is a start-up developing a CE-marked microbiome-based in vitro diagnostic to predict the response to immune checkpoint inhibitors.

🔹Osasuna is a biotech developing mAbs neutralizing ACBP/DBI, which has been highly elevated in various pathologies, such as cancers and responsible of feedback inhibition of cell autophagy.

🔹BioSyngen is a Singapore-based clinical-stage biotech specializing in the development of innovative cell therapies (Chimeric Antigen Receptor T-cell (CAR-T), T-cell Receptor T-cell (TCR-T), and Tumor-Infiltrating Lymphocytes (TIL) therapies for cancer treatment.

🔹Cellura is a biotech focusing on disruptive cell therapy manufacturing ; their low-shear bioreactor addresses the challenge of sensitive cells expansion.

🔹One Biosciences is a techbio using single-cell technologies and AI to provide high-resolution omics profiling for precision medicine.

Congratulations to all team members for their remarkable innovations! 👏

With over 60 cutting-edge oncology projects selected and supported, the PSCC provides the most promising initiatives with a comprehensive range of resources, including expertise, networking, financing, data, samples, technologies, infrastructures, training, and laboratories. Our mission is to transform breakthrough approaches into impactful industrial diagnostic and therapeutic solutions to fight cancer.